BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24118729)

  • 1. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
    Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
    Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of tumor budding detection in stage II colon cancer].
    Liu SJ; Yang XH; Ren JQ; Zhu XJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):730-4. PubMed ID: 23980042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
    Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
    Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer.
    Betge J; Kornprat P; Pollheimer MJ; Lindtner RA; Schlemmer A; Rehak P; Vieth M; Langner C
    Ann Surg Oncol; 2012 Nov; 19(12):3706-12. PubMed ID: 22669453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma.
    Park KJ; Choi HJ; Roh MS; Kwon HC; Kim C
    Dis Colon Rectum; 2005 Aug; 48(8):1597-602. PubMed ID: 15937624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour budding at invasive margins and outcome in colorectal cancer.
    Kanazawa H; Mitomi H; Nishiyama Y; Kishimoto I; Fukui N; Nakamura T; Watanabe M
    Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
    Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
    Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
    Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
    Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
    Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
    Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic prognostic markers in stage IIA colorectal cancer: a comparative study.
    Barresi V; Reggiani Bonetti L; Ieni A; Branca G; Tuccari G
    Scand J Gastroenterol; 2016 Mar; 51(3):314-20. PubMed ID: 26554618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor budding and survival after potentially curative resection of node-positive colon cancer.
    Sy J; Fung CL; Dent OF; Chapuis PH; Bokey L; Chan C
    Dis Colon Rectum; 2010 Mar; 53(3):301-7. PubMed ID: 20173477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens.
    Martinez-Ciarpaglini C; Fernandez-Sellers C; Tarazona N; Roselló S; Huerta M; Roda D; Mongort C; Ferrández A; Navarro S; Cervantes A
    Histopathology; 2019 Oct; 75(4):517-525. PubMed ID: 31081121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
    Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.
    Höckel M; Hentschel B; Horn LC
    Lancet Oncol; 2014 Apr; 15(4):445-56. PubMed ID: 24656439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients.
    Andreoni B; Chiappa A; Bertani E; Bellomi M; Orecchia R; Zampino M; Fazio N; Venturino M; Orsi F; Sonzogni A; Pace U; Monfardini L
    World J Surg Oncol; 2007 Jul; 5():73. PubMed ID: 17610720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
    Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.
    Wang LM; Kevans D; Mulcahy H; O'Sullivan J; Fennelly D; Hyland J; O'Donoghue D; Sheahan K
    Am J Surg Pathol; 2009 Jan; 33(1):134-41. PubMed ID: 18971777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.